Financhill
Sell
34

FBIO Quote, Financials, Valuation and Earnings

Last price:
$1.89
Seasonality move :
-8.91%
Day range:
$1.76 - $1.86
52-week range:
$1.33 - $2.89
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.72x
P/B ratio:
2.43x
Volume:
86.2K
Avg. volume:
214K
1-year change:
9.58%
Market cap:
$54.1M
Revenue:
$57.7M
EPS (TTM):
-$2.23

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
FBIO
Fortress Biotech
$14.5M -$0.31 -2.43% -57.53% $10.00
DERM
Journey Medical
$14.9M -- 0.53% -- $9.75
NBY
NovaBay Pharmaceuticals
$3M -$0.88 14.03% -95.43% $0.85
NNVC
Nanoviricides
-- -$0.20 -- -26.67% --
OGEN
Oragenics
-- -- -- -- $1.00
TOVX
Theriva Biologics
-- -$0.47 -- -95.63% $7.00
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
FBIO
Fortress Biotech
$1.83 $10.00 $54.1M -- $0.00 0% 0.72x
DERM
Journey Medical
$7.04 $9.75 $164M -- $0.00 0% 2.64x
NBY
NovaBay Pharmaceuticals
$0.63 $0.85 $3.6M -- $0.00 0% 0.16x
NNVC
Nanoviricides
$1.39 -- $22.3M -- $0.00 0% --
OGEN
Oragenics
$1.44 $1.00 $1M -- $0.00 0% 0.46x
TOVX
Theriva Biologics
$0.45 $7.00 $3.7M -- $0.00 0% 0.33x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
FBIO
Fortress Biotech
72.36% 0.018 103.39% 1.49x
DERM
Journey Medical
53.7% -0.001 18.33% 0.97x
NBY
NovaBay Pharmaceuticals
4.54% -0.044 1.51% 0.75x
NNVC
Nanoviricides
-- -0.318 -- --
OGEN
Oragenics
-- 0.068 -- --
TOVX
Theriva Biologics
-- -3.388 -- --
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
FBIO
Fortress Biotech
$8.3M -$22.3M -67.58% -- -168.82% -$19.6M
DERM
Journey Medical
$8.3M -$3.3M -22.96% -54.07% -24.22% -$2.8M
NBY
NovaBay Pharmaceuticals
$1.6M -$2.7M -334.47% -461.38% -44% -$1.3M
NNVC
Nanoviricides
-- -$2.2M -- -- -- -$2M
OGEN
Oragenics
-- -$2M -- -- -- -$2.1M
TOVX
Theriva Biologics
-- -$4.4M -- -- -- -$4.8M

Fortress Biotech vs. Competitors

  • Which has Higher Returns FBIO or DERM?

    Journey Medical has a net margin of -80.55% compared to Fortress Biotech's net margin of -31%. Fortress Biotech's return on equity of -- beat Journey Medical's return on equity of -54.07%.

    Company Gross Margin Earnings Per Share Invested Capital
    FBIO
    Fortress Biotech
    63.54% -$0.48 $90.7M
    DERM
    Journey Medical
    63.54% -$0.18 $46.5M
  • What do Analysts Say About FBIO or DERM?

    Fortress Biotech has a consensus price target of $10.00, signalling upside risk potential of 446.45%. On the other hand Journey Medical has an analysts' consensus of $9.75 which suggests that it could grow by 38.49%. Given that Fortress Biotech has higher upside potential than Journey Medical, analysts believe Fortress Biotech is more attractive than Journey Medical.

    Company Buy Ratings Hold Ratings Sell Ratings
    FBIO
    Fortress Biotech
    1 0 0
    DERM
    Journey Medical
    3 0 0
  • Is FBIO or DERM More Risky?

    Fortress Biotech has a beta of 1.752, which suggesting that the stock is 75.204% more volatile than S&P 500. In comparison Journey Medical has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock FBIO or DERM?

    Fortress Biotech has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Journey Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Fortress Biotech pays -10.24% of its earnings as a dividend. Journey Medical pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios FBIO or DERM?

    Fortress Biotech quarterly revenues are $13.1M, which are smaller than Journey Medical quarterly revenues of $13.1M. Fortress Biotech's net income of -$10.6M is lower than Journey Medical's net income of -$4.1M. Notably, Fortress Biotech's price-to-earnings ratio is -- while Journey Medical's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fortress Biotech is 0.72x versus 2.64x for Journey Medical. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    FBIO
    Fortress Biotech
    0.72x -- $13.1M -$10.6M
    DERM
    Journey Medical
    2.64x -- $13.1M -$4.1M
  • Which has Higher Returns FBIO or NBY?

    NovaBay Pharmaceuticals has a net margin of -80.55% compared to Fortress Biotech's net margin of -49.65%. Fortress Biotech's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.

    Company Gross Margin Earnings Per Share Invested Capital
    FBIO
    Fortress Biotech
    63.54% -$0.48 $90.7M
    NBY
    NovaBay Pharmaceuticals
    65.26% $1.42 $1.1M
  • What do Analysts Say About FBIO or NBY?

    Fortress Biotech has a consensus price target of $10.00, signalling upside risk potential of 446.45%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 35.98%. Given that Fortress Biotech has higher upside potential than NovaBay Pharmaceuticals, analysts believe Fortress Biotech is more attractive than NovaBay Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    FBIO
    Fortress Biotech
    1 0 0
    NBY
    NovaBay Pharmaceuticals
    1 0 0
  • Is FBIO or NBY More Risky?

    Fortress Biotech has a beta of 1.752, which suggesting that the stock is 75.204% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.443, suggesting its less volatile than the S&P 500 by 55.681%.

  • Which is a Better Dividend Stock FBIO or NBY?

    Fortress Biotech has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Fortress Biotech pays -10.24% of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios FBIO or NBY?

    Fortress Biotech quarterly revenues are $13.1M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Fortress Biotech's net income of -$10.6M is lower than NovaBay Pharmaceuticals's net income of $7.7M. Notably, Fortress Biotech's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fortress Biotech is 0.72x versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    FBIO
    Fortress Biotech
    0.72x -- $13.1M -$10.6M
    NBY
    NovaBay Pharmaceuticals
    0.16x -- $2.4M $7.7M
  • Which has Higher Returns FBIO or NNVC?

    Nanoviricides has a net margin of -80.55% compared to Fortress Biotech's net margin of --. Fortress Biotech's return on equity of -- beat Nanoviricides's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    FBIO
    Fortress Biotech
    63.54% -$0.48 $90.7M
    NNVC
    Nanoviricides
    -- -$0.14 --
  • What do Analysts Say About FBIO or NNVC?

    Fortress Biotech has a consensus price target of $10.00, signalling upside risk potential of 446.45%. On the other hand Nanoviricides has an analysts' consensus of -- which suggests that it could grow by 367.63%. Given that Fortress Biotech has higher upside potential than Nanoviricides, analysts believe Fortress Biotech is more attractive than Nanoviricides.

    Company Buy Ratings Hold Ratings Sell Ratings
    FBIO
    Fortress Biotech
    1 0 0
    NNVC
    Nanoviricides
    0 0 0
  • Is FBIO or NNVC More Risky?

    Fortress Biotech has a beta of 1.752, which suggesting that the stock is 75.204% more volatile than S&P 500. In comparison Nanoviricides has a beta of 0.882, suggesting its less volatile than the S&P 500 by 11.802%.

  • Which is a Better Dividend Stock FBIO or NNVC?

    Fortress Biotech has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nanoviricides offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Fortress Biotech pays -10.24% of its earnings as a dividend. Nanoviricides pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios FBIO or NNVC?

    Fortress Biotech quarterly revenues are $13.1M, which are larger than Nanoviricides quarterly revenues of --. Fortress Biotech's net income of -$10.6M is lower than Nanoviricides's net income of -$2.2M. Notably, Fortress Biotech's price-to-earnings ratio is -- while Nanoviricides's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fortress Biotech is 0.72x versus -- for Nanoviricides. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    FBIO
    Fortress Biotech
    0.72x -- $13.1M -$10.6M
    NNVC
    Nanoviricides
    -- -- -- -$2.2M
  • Which has Higher Returns FBIO or OGEN?

    Oragenics has a net margin of -80.55% compared to Fortress Biotech's net margin of --. Fortress Biotech's return on equity of -- beat Oragenics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    FBIO
    Fortress Biotech
    63.54% -$0.48 $90.7M
    OGEN
    Oragenics
    -- -$3.60 --
  • What do Analysts Say About FBIO or OGEN?

    Fortress Biotech has a consensus price target of $10.00, signalling upside risk potential of 446.45%. On the other hand Oragenics has an analysts' consensus of $1.00 which suggests that it could grow by 1983.54%. Given that Oragenics has higher upside potential than Fortress Biotech, analysts believe Oragenics is more attractive than Fortress Biotech.

    Company Buy Ratings Hold Ratings Sell Ratings
    FBIO
    Fortress Biotech
    1 0 0
    OGEN
    Oragenics
    0 1 0
  • Is FBIO or OGEN More Risky?

    Fortress Biotech has a beta of 1.752, which suggesting that the stock is 75.204% more volatile than S&P 500. In comparison Oragenics has a beta of 0.946, suggesting its less volatile than the S&P 500 by 5.446%.

  • Which is a Better Dividend Stock FBIO or OGEN?

    Fortress Biotech has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Fortress Biotech pays -10.24% of its earnings as a dividend. Oragenics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios FBIO or OGEN?

    Fortress Biotech quarterly revenues are $13.1M, which are larger than Oragenics quarterly revenues of --. Fortress Biotech's net income of -$10.6M is lower than Oragenics's net income of -$2.2M. Notably, Fortress Biotech's price-to-earnings ratio is -- while Oragenics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fortress Biotech is 0.72x versus 0.46x for Oragenics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    FBIO
    Fortress Biotech
    0.72x -- $13.1M -$10.6M
    OGEN
    Oragenics
    0.46x -- -- -$2.2M
  • Which has Higher Returns FBIO or TOVX?

    Theriva Biologics has a net margin of -80.55% compared to Fortress Biotech's net margin of --. Fortress Biotech's return on equity of -- beat Theriva Biologics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    FBIO
    Fortress Biotech
    63.54% -$0.48 $90.7M
    TOVX
    Theriva Biologics
    -- -$1.55 --
  • What do Analysts Say About FBIO or TOVX?

    Fortress Biotech has a consensus price target of $10.00, signalling upside risk potential of 446.45%. On the other hand Theriva Biologics has an analysts' consensus of $7.00 which suggests that it could grow by 1455.56%. Given that Theriva Biologics has higher upside potential than Fortress Biotech, analysts believe Theriva Biologics is more attractive than Fortress Biotech.

    Company Buy Ratings Hold Ratings Sell Ratings
    FBIO
    Fortress Biotech
    1 0 0
    TOVX
    Theriva Biologics
    1 1 0
  • Is FBIO or TOVX More Risky?

    Fortress Biotech has a beta of 1.752, which suggesting that the stock is 75.204% more volatile than S&P 500. In comparison Theriva Biologics has a beta of 0.816, suggesting its less volatile than the S&P 500 by 18.373%.

  • Which is a Better Dividend Stock FBIO or TOVX?

    Fortress Biotech has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Fortress Biotech pays -10.24% of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios FBIO or TOVX?

    Fortress Biotech quarterly revenues are $13.1M, which are larger than Theriva Biologics quarterly revenues of --. Fortress Biotech's net income of -$10.6M is lower than Theriva Biologics's net income of -$4.3M. Notably, Fortress Biotech's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fortress Biotech is 0.72x versus 0.33x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    FBIO
    Fortress Biotech
    0.72x -- $13.1M -$10.6M
    TOVX
    Theriva Biologics
    0.33x -- -- -$4.3M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Where Will Hershey Stock Be In 1 Year?
Where Will Hershey Stock Be In 1 Year?

Chocolate stocks used to be the epitome of sleepy stability,…

Where Will KNOT Stock Be In 1 Year?
Where Will KNOT Stock Be In 1 Year?

In the case of KNOT Offshore Partners (KNOP), most headlines…

Why Is Goldman Sachs Stock Up So Much?
Why Is Goldman Sachs Stock Up So Much?

Investment banking giant Goldman Sachs (NYSE:GS) has sharply outperformed the…

Stock Ideas

Buy
63
Is NVDA Stock a Buy?

Market Cap: $3.8T
P/E Ratio: 53x

Buy
60
Is MSFT Stock a Buy?

Market Cap: $3.7T
P/E Ratio: 42x

Sell
48
Is AAPL Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 35x

Alerts

Buy
92
BGL alert for Jul 3

Blue Gold [BGL] is down 20.3% over the past day.

Sell
18
CNC alert for Jul 3

Centene [CNC] is down 1.3% over the past day.

Sell
12
MOH alert for Jul 3

Molina Healthcare [MOH] is up 0.3% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock